<p>BEAS-2B cells were either left untransfected (Utx), transfected with a non-targeting scrambled control siRNA (Scr) or siRNA targeting p85α and p85β at 100 nM. After 48 h transfection, cells were infected with RV-1B at the indicated TCID<sub>50</sub>/ml for 1 h (following which supernatants were replaced with media) (B, C), or stimulated with poly(I:C) at the indicated concentrations (D, E). Cells were then cultured for 24 h. (A) Whole-cell lysates were analysed by western blot using Abs specific to p85α, p85β or actin. Data are representative of 3 (for HRV) and 2 (Poly(I:C)) independent experiments, each replicate was performed on a separate passage of cells. CXCL8 (B, D) and CCL5 (C, E) release was measured by ELISA. Significant differe...
<p>(<b>A</b>) HR Assay design. I-<i>Sce</i>I sites are indicated by white triangle heads. The locati...
<p>(A) HeLa cells were transfected with individual TRAPPC8 siRNAs (KIAA1012-01, -02, -03, or -04). A...
<p>Primary MDMs (1×10<sup>6</sup> cells/ml) from 34 healthy donors were treated with HRV16 or HRV1A ...
<p>BEAS-2B cells were either left untransfected (Utx), or transfected with a non-targeting scrambled...
<p>BEAS-2B cells were either left untransfected (Utx), or transfected with a non-targeting scrambled...
<p>BEAS-2B cells were either left untransfected (Utx), transfected with a non-targeting scrambled co...
<p>BEAS-2B cells were infected with RV-1B or RV-16 at 1×10<sup>7</sup> TCID<sub>50</sub>/ml for 1 h ...
<p>BEAS-2B cells were left uninfected (A, D); or infected with RV-1B (B, E) or RV-16 (C, F) at 1×10<...
<p>BEAS-2B cells were left uninfected (A, D); or infected with RV-1B (B, E) or RV-16 (C, F) at 1×10<...
<p>BEAS-2B cells were infected with RV-16 at 1×10<sup>7</sup> TCID<sub>50</sub>/ml for 1 h (followin...
(A) Transfection of non-targeting siRNA (siNT) or SFPQ-targeting siRNA (siSFPQ) did not result in st...
<p>(A) Summary of genetic alterations in PC9 and PC9/AZDR cells. (B) Cell viability was measured by ...
<p>(A) Western blot analysis of cleaved PARP in HCV-infected cells. Whole cell lysates extracted fro...
<p>HNEC were exposed apically to HRV14 alone (HRV), or co-cultured with activated T cells alone (T c...
<p>(<b>A</b>) HT-1080 cells were irradiated (5 Gy) for the indicated period of time, and then cell l...
<p>(<b>A</b>) HR Assay design. I-<i>Sce</i>I sites are indicated by white triangle heads. The locati...
<p>(A) HeLa cells were transfected with individual TRAPPC8 siRNAs (KIAA1012-01, -02, -03, or -04). A...
<p>Primary MDMs (1×10<sup>6</sup> cells/ml) from 34 healthy donors were treated with HRV16 or HRV1A ...
<p>BEAS-2B cells were either left untransfected (Utx), or transfected with a non-targeting scrambled...
<p>BEAS-2B cells were either left untransfected (Utx), or transfected with a non-targeting scrambled...
<p>BEAS-2B cells were either left untransfected (Utx), transfected with a non-targeting scrambled co...
<p>BEAS-2B cells were infected with RV-1B or RV-16 at 1×10<sup>7</sup> TCID<sub>50</sub>/ml for 1 h ...
<p>BEAS-2B cells were left uninfected (A, D); or infected with RV-1B (B, E) or RV-16 (C, F) at 1×10<...
<p>BEAS-2B cells were left uninfected (A, D); or infected with RV-1B (B, E) or RV-16 (C, F) at 1×10<...
<p>BEAS-2B cells were infected with RV-16 at 1×10<sup>7</sup> TCID<sub>50</sub>/ml for 1 h (followin...
(A) Transfection of non-targeting siRNA (siNT) or SFPQ-targeting siRNA (siSFPQ) did not result in st...
<p>(A) Summary of genetic alterations in PC9 and PC9/AZDR cells. (B) Cell viability was measured by ...
<p>(A) Western blot analysis of cleaved PARP in HCV-infected cells. Whole cell lysates extracted fro...
<p>HNEC were exposed apically to HRV14 alone (HRV), or co-cultured with activated T cells alone (T c...
<p>(<b>A</b>) HT-1080 cells were irradiated (5 Gy) for the indicated period of time, and then cell l...
<p>(<b>A</b>) HR Assay design. I-<i>Sce</i>I sites are indicated by white triangle heads. The locati...
<p>(A) HeLa cells were transfected with individual TRAPPC8 siRNAs (KIAA1012-01, -02, -03, or -04). A...
<p>Primary MDMs (1×10<sup>6</sup> cells/ml) from 34 healthy donors were treated with HRV16 or HRV1A ...